LRRK2 and Parkinson disease: Compared to expression of wildtype LRRK2, the pathogenic Y1699C-LRRK2 mutant caused a pronounced deficit in centrosomal cohesion, which was significantly reduced by transient application of the LRRK2 kinase inhibitor MLi2 (Fig. S3A,B), and mild but statistically significant cohesion deficits were also observed when expressing the four distinct LRRK2 PD risk variants (Fig. S3A,B).